Skip to Content

Gilead Sciences Inc GILD

Morningstar Rating
$69.97 +1.22 (1.77%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Gilead's HIV Dominance and Growing Oncology Portfolio Support a Wide Moat

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and pipeline support a wide moat, but Gilead needs HCV market stabilization, strong continued innovation in HIV, solid pipeline data, and smart future acquisitions to return to growth.

Price vs Fair Value

GILD is trading at a 289% premium.
Price
$69.97
Fair Value
$11.00
Uncertainty
Medium
1-Star Price
$447.52
5-Star Price
$37.10
Economic Moat
Ncnk
Capital Allocation
Xvnhhpzrx

Bulls Say, Bears Say

Bulls

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.

Bears

Biktarvy's success creates a patent cliff in 2033, and it could be difficult to improve on this daily HIV drug regimen.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GILD is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$68.75
Day Range
$68.1470.30
52-Week Range
$62.0787.87
Bid/Ask
$70.10 / $70.28
Market Cap
$87.17 Bil
Volume/Avg
527 / 7.6 Mil

Key Statistics

Price/Earnings (Normalized)
17.36
Price/Sales
3.20
Dividend Yield (Trailing)
4.34%
Dividend Yield (Forward)
4.40%
Total Yield
5.17%

Company Profile

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Value
Total Number of Employees
18,000

Competitors

Valuation

Metric
GILD
MRK
GSK
Price/Earnings (Normalized)
17.3659.439.60
Price/Book Value
4.978.094.54
Price/Sales
3.205.352.07
Price/Cash Flow
8.2018.819.39
Price/Earnings
GILD
MRK
GSK

Financial Strength

Metric
GILD
MRK
GSK
Quick Ratio
0.720.680.57
Current Ratio
1.081.250.87
Interest Coverage
2.113.978.94
Quick Ratio
GILD
MRK
GSK

Profitability

Metric
GILD
MRK
GSK
Return on Assets (Normalized)
8.33%5.22%11.25%
Return on Equity (Normalized)
24.25%13.56%51.21%
Return on Invested Capital (Normalized)
12.71%8.29%22.40%
Return on Assets
GILD
MRK
GSK
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
WpxnmswhZmw$841.1 Bil
Johnson & Johnson
JNJ
SfhrgzlVzkxb$360.3 Bil
Merck & Co Inc
MRK
WsdlhkdfFnnl$326.7 Bil
AbbVie Inc
ABBV
MjrlmgqljGnqt$300.0 Bil
AstraZeneca PLC ADR
AZN
XqjmpdmsyQhd$241.1 Bil
Roche Holding AG ADR
RHHBY
XsmnqzlzvSpbdd$226.6 Bil
Novartis AG ADR
NVS
YlslkytgGtv$225.2 Bil
Amgen Inc
AMGN
YtrqlxnnvyGlxxw$174.4 Bil
Pfizer Inc
PFE
RmpcvmwdFmpw$162.4 Bil
Sanofi SA ADR
SNY
HcyjzhlBtmq$127.1 Bil

Sponsor Center